ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)

South Korea · Delayed Price · Currency is KRW

2,890.00

+85.00 (3.03%)

At close: Sep 4, 2026

Market Cap	263.97B -36.0%
Revenue (ttm)	n/a -83.0%
Net Income	-29.31B
EPS	-385.56
Shares Out	91.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,974
Open	2,835.00
Previous Close	2,805.00
Day's Range	2,800.00 - 2,985.00
52-Week Range	2,300.00 - 16,110.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ImmuneOncia Therapeutics

ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, su... [Read more]

Industry Pharmaceutical Preparations

Founded 2016

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 424870

Full Company Profile

Financial Performance

In 2025, ImmuneOncia Therapeutics's revenue was 111.21 million, a decrease of -83.01% compared to the previous year's 654.54 million. Losses were -27.36 billion, 381.2% more than in 2024.

Financial Statements